Member Info for Brand

Essential viewing:)

https://www.workcast.com/register?cpak=5925937036589485

No. It's increased.

What a mess this place is.

If we are working on the basis that the US market is key, this week is Thanksgiving w both yesterday and today a public holiday. The world vaccine and immunology event starts Monday, w P Monk speaking on Wednesday

https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/speaker-phillip-MONK.stm

https://twitter.com/respfutures/status/1595435755387641856?t=ysA4JzS3vT4n5yuKbuOEAA&s=19

https://www.respiratoryfutures.org.uk/programmes/lungs-matter/

https://twitter.com/respfutures/status/1594986544980426752?t=_t20siLLYUSmVgtZMcFLUA&s=19

"This week at the #BTSWinter2022 conference we will be premiering #LungsMatter, made with @ITNBusiness and @BTSrespiratory. The programme looks at the technology and innovations that are impacting patient outcomes. The full programme will become available to watch on our website."

https://twitter.com/Synairgenplc/status/1594970434436755456?t=b-QvjZYwhbWBFZ10NUA9VA&s=19

Haven't seen anything relating to this. Got a link or info Billy?

Our friends at market screener seem to think so

https://m.marketscreener.com/quote/stock/SYNAIRGEN-PLC-4004905/company/

The other data all looks to be up to date as well.

Ghia - to add a bit of meat to the bone of my speculation, I think this paper and the method behind it are part of/involved w the Janssen trial

https://www.frontiersin.org/articles/10.3389/fimmu.2022.988685/full

Nailed it Gunto.

Giving it large as some others have done w small or suspect data sets would no doubt pump the SP in the short term but the goal here is commercialisation, not pump and dump

Ghia

It's a fair point re any treatments Janssen have the in the pipeline, but the question begs why not just run the trial themselves, considering the vast resources available.

This moves in to speculation, but I personally believe at least part of the trial is designed to inform on the ability to predict which patients presenting in hospital w respiratory infection will progress to severe disease.

Ghia - can't be bothered to dig it up, but very distinctly recall your take on the universal trial as Janssen 'sizing the market' of sng001 - I recall it well because I generally agree. It's the most logical solution, and I expect you're right that it's also bringing a bit of revenue (in kind) to the company.

The shoe certainly looks to fit

The job ads shared by Titania are for St Mike's hospital in Toronto, one of the trial sites in this new Canadian PT.

The university of Southampton is included as a partner on the PT website - it's the only foreign organisation included.

https://www.bmj.com/content/379/bmj.o2759

NICE has recommended three drugs—nirmatrelvir plus ritonavir (Paxlovid), tocilizumab (RoActemra), and baricitinib (Olumiant)—for the treatment of covid-19 in adults, as part of draft guidance.1

The review of the efficacy and cost effectiveness of drugs currently being used in the NHS to treat covid-19 considered treatments in the context of routine commissioning, rather than their use in exceptional circumstances, such as during a pandemic.

NICE has not recommended other covid-19 treatments, including casirivimab plus imdevimab (Ronapreve), molnupiravir (Lagevrio), remdesivir (Veklury), sotrovimab (Xevudy), and tixagevimab plus cilgavimab (Evusheld).

Currently, access to covid-19 drugs is guided by the UK wide clinical access policies agreed by the UK chief medical officers. Once the final NICE guidance is published, however, it will inform routine commissioning decisions for these treatments.

Tommy I think that's sound reasoning, however if on the back of Activ and the PASC results Health Canada wants to trial sng001 in outpatients at no cost to the company - w a view to approval in a G7 economy - then I would certainly hope the company would agree.

Expect there isn't much that would get the FDA to move faster than their friendly neighbors to the north getting a hold of a breakthrough respiratory treatment.

It's open label so my expectation is they want to compare it vs other treatments

https://clinicaltrials.gov/ct2/show/NCT05614349?recrs=b&cond=COVID-19&phase=2&draw=13&rank=68

...Is tomorrow

https://goldcopd.org/world-copd-day-2022/

Have a nice day :)